Alerts will be sent to your verified email
Verify EmailGOLDLINE
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Goldline Pharmaceuticals Ltd., established in 2021, markets pharmaceutical and wellness products under the “Goldline” brand through third-party manufacturing partnerships. The company focuses on quality-driven distribution, healthcare supply solutions, and efficient pharmaceutical procurement services.
Goldline Pharmaceuti major competitors are Mono Pharmacare, Chandra Bhagat Pharm.
Market Cap of Goldline Pharmaceuti is ₹54 Crs.
While the median market cap of its peers are ₹23 Crs.
Goldline Pharmaceuti seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | |||||||||||||||||||
| Investor Presentation | |||||||||||||||||||
| Conference Call | |||||||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
